GE Healthcare (NYSE:GE) today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility. Optison is a contrast agent that may improve the visualization of the left ventricular border - an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. Upon approval, GE Healthcare will provide supply of Optison to the US market from its manufacturing facility in Oslo, becoming the only contrast media manufacturer to supply its own stock for the US.
Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve delineation of the left ventricular endocardial borders. Optison is not for use in patients with known or suspected: (1) Right-to-left, bi-directional, or transient right-to-left cardiac shunts, or (2) hypersensitivity to perflutren, blood, blood products or albumin. It should not be administered by intra-arterial injection. As for all ultrasound contrast agents, Optison has a boxed warning indicating that serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Healthcare professionals should assess all patients for the presence of any condition that precludes Optison administration and always have resuscitation equipment and trained personnel readily available.
"GE Healthcare is committed to providing safe, innovative, and effective medical products that aid in the detection of cardiovascular diseases, and today's filing is further evidence of that commitment," said Stephen Lightfoot, General Manager, Core Imaging, GE Healthcare Medical Diagnostics. "While we cannot predict a timeline for regulatory authority approval, we look forward to servicing the US cardiology community directly in 2013."